Allianz Asset Management GmbH Buys New Shares in Heartflow, Inc. $HTFL

Key Points

• Allianz Asset Management initiated a Heartflow position of 53,061 shares worth approximately $1.56 million, joining several other major investors that recently built or expanded stakes.
• Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, and an adjusted loss of $0.07 per share that beat estimates of a $0.22 loss. Despite strong growth, the company remains unprofitable with a negative net margin of 55.82%.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $44.88. However, insiders have sold 202,125 shares worth $8.1 million over the past 90 days, while the stock recently traded at $46.67.

Allianz Asset Management GmbH bought a new position in Heartflow, Inc. (NASDAQ:HTFL - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 53,061 shares of the company's stock, valued at approximately $1,557,000. Allianz Asset Management GmbH owned about 0.06% of Heartflow at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. XXEC Inc. purchased a new position in shares of Heartflow in the second quarter worth about $2,524,764,000. Wellington Management Group LLP increased its stake in shares of Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company's stock worth $171,812,000 after acquiring an additional 1,014,006 shares during the period. BlackRock Inc. acquired a new stake in shares of Heartflow in the second quarter worth $152,502,000. Bamco Inc. NY purchased a new position in shares of Heartflow during the second quarter worth $94,625,000. Finally, Jupiter Topco LLC acquired a new position in Heartflow during the second quarter valued at $70,983,000.

Insiders Place Their Bets

In other Heartflow news, CFO Vikram Verghese sold 27,540 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $49.69, for a total transaction of $1,368,462.60. Following the transaction, the chief financial officer directly owned 221,143 shares of the company's stock, valued at $10,988,595.67. This trade represents a 11.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the completion of the sale, the insider owned 86,459 shares in the company, valued at approximately $3,564,704.57. This trade represents a 9.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 202,125 shares of company stock worth $8,111,907. Company insiders own 7.70% of the company's stock.

Heartflow Trading Down 2.3%

Shares of HTFL stock opened at $46.67 on Thursday. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $51.78. The business's 50 day moving average is $34.73 and its two-hundred day moving average is $30.50. The company has a market capitalization of $4.06 billion and a P/E ratio of -25.50.

Heartflow (NASDAQ:HTFL - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The business had revenue of $64.08 million during the quarter. The business's revenue was up 47.7% compared to the same quarter last year. On average, research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their price target on Heartflow from $37.00 to $39.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. JPMorgan Chase & Co. upped their target price on Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a research note on Friday, August 14th. Canaccord Genuity Group raised their target price on Heartflow from $37.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, August 14th. UBS Group began coverage on Heartflow in a research report on Wednesday. They set a "neutral" rating and a $55.00 price target for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $45.00 price target (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $44.88.

Heartflow Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.